Synthesis of quinazolines as tyrosine kinase inhibitors.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Anti-Cancer Agents in Medicinal Chemistry

• Publication date

  2009-02-28

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.2174/1871520610909030246PMID 19275520
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inhibitors of epidermal growth factor receptor tyrosine kinase: Novel C-5 substituted anilinoquinazolines designed to target the ribose pocket.

  2006cited by this paper
• 2-(Quinazolin-4-ylamino)-[1,4]benzoquinones as covalent-binding, irreversible inhibitors of the kinase domain of vascular endothelial growth factor receptor-2.

  2005cited by this paper
• Synthesis and antitumor evaluation of novel 5-substituted-4-hydroxy-8-nitroquinazolines as EGFR signaling-targeted inhibitors.

  2005cited by this paper
• Recent advances in tumor-targeting anticancer drug conjugates.

  2005cited by this paper
• 5-Substituted 4-anilinoquinazolines as potent, selective and orally active inhibitors of erbB2 receptor tyrosine kinase.

  2005cited by this paper
• 4-Anilinoquinazolines with Lavendustin A subunit as inhibitors of epidermal growth factor receptor tyrosine kinase: syntheses, chemical and pharmacological properties.

  2004cited by this paper
• Identification of 4-piperazin-1-yl-quinazoline template based aryl and benzyl thioureas as potent, selective, and orally bioavailable inhibitors of platelet-derived growth factor (PDGF) receptor.

  2004cited by this paper
• Potent and selective inhibitors of platelet-derived growth factor receptor phosphorylation. 3. Replacement of quinazoline moiety and improvement of metabolic polymorphism of 4-[4-(N-substituted (thio)carbamoyl)-1-piperazinyl]-6,7-dimethoxyquinazoline derivatives.

  2003cited by this paper
• Potent and selective inhibitors of platelet-derived growth factor receptor phosphorylation. Part 4: structure-activity relationships for substituents on the quinazoline moiety of 4-[4-(N-substituted(thio)carbamoyl)-1-piperazinyl]-6,7-dimethoxyquinazoline derivatives.

  2003cited by this paper
• Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors.

  2002cited by this paper
• Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family.

  2002cited by this paper
• Potent and selective inhibitors of platelet-derived growth factor receptor phosphorylation. 1. Synthesis, structure-activity relationship, and biological effects of a new class of quinazoline derivatives.

  2002cited by this paper
• Potent and selective inhibitors of PDGF receptor phosphorylation. 2. Synthesis, structure activity relationship, improvement of aqueous solubility, and biological effects of 4-[4-(N-substituted (thio)carbamoyl)-1-piperazinyl]-6,7-dimethoxyquinazoline derivatives.

  2002cited by this paper
• Efficacy of the novel selective platelet-derived growth factor receptor antagonist CT52923 on cellular proliferation, migration, and suppression of neointima following vascular injury.

  2001cited by this paper
• 6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity.

  2001cited by this paper
• Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor.

  2001cited by this paper
• Chemical inhibitors of protein kinases.

  2001cited by this paper
• Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2.

  2001cited by this paper
• Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer.

  2001cited by this paper
• Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions.

  2000cited by this paper
• From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents

  2000cited by this paper
• Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785).

  1999cited by this paper
• Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor.

  1999cited by this paper
• Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors.

  1999cited by this paper
• Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.

  1998cited by this paper
• Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor.

  1998cited by this paper
• Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrolo- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: synthesis, biological evaluation, and modeling of the mode of binding.

  1997cited by this paper
• STRUCTURE‐ACTIVITY RELATIONSHIPS FOR 4‐ANILINOQUINAZOLINES AS POTENT INHIBITORS AT THE ATP BINDING SITE OF THE EPIDERMAL GROWTH FACTOR RECEPTOR IN VITRO

  1996cited by this paper
• Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor.

  1996cited by this paper
• Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor.

  1996cited by this paper
• Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.

  1996cited by this paper
• Enantioselective inhibition of the epidermal growth factor receptor tyrosine kinase by 4-(alpha-phenethylamino)quinazolines.

  1995cited by this paper
• Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5'-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor.

  1995cited by this paper
• A specific inhibitor of the epidermal growth factor receptor tyrosine kinase.

  1994cited by this paper
• Isolation of a novel tyrosine kinase inhibitor, lavendustin A, from Streptomyces griseolavendus.

  1989cited by this paper
• Synthesis and identification of the major metabolites of prazosin formed in dog and rat.

  1977cited by this paper

• Novel quinazolines bearing 1,3,4-thiadiazole-aryl urea derivative as anticancer agents: design, synthesis, molecular docking, DFT and bioactivity evaluations

  2024cites this paper
• Synthesis of 2-Amino-quinazolin-4(3H)-ones Using 2-Bromo-N-phenylbenzamide and Cyanamide Ullmann Cross-Coupling.

  2024cites this paper
• Synthesis of 2,3-dihydro-4(1H) quinazolinones using a magnetic pectin-supported deep eutectic solvent

  2022cites this paper
• An appraisal of anticancer activity with structure–activity relationship of quinazoline and quinazolinone analogues through EGFR and VEGFR inhibition: A review

  2022cites this paper
• The p53 stabilizing agent CP-31398 and multi-kinase inhibitors. Designing, synthesizing and screening of styrylquinazoline series.

  2019cites this paper
• Synthesis, characterization, and antimicrobial activity of novel hydrazone-bearing tricyclic quinazolines

  2019cites this paper
• Synthesis, Characterization, Molecular Docking Studies and Biological Evaluation of Some Conjugated Quinazoline-Sulfonamide Scaffold

  2018cites this paper
• Regioselective synthesis and biological evaluation of N-substituted 2-aminoquinazolin-4-ones.

  2018cites this paper
• Synthesis, characterization, crystal structure, Hirshfeld interaction and bio-evaluation studies of 4-amino quinazoline sulfonamide derivatives

  2018cites this paper
• Design, Synthesis and Anticancer Evaluation of Novel Quinazoline-Sulfonamide Hybrids

  2016cites this paper
• Synthesis, antibacterial activities evaluation, and docking studies of some 2-substituted-3-(phenylamino)-dihydroquinazolin-4(1H)-ones

  2015cites this paper
• Rationally designed multitarget anticancer agents.

  2013cites this paper
• Kinase Inhibitors in Cancer

  2013cites this paper
• Microwave-assisted, sequential four-component synthesis of polysubstituted 5,6-dihydroquinazolinones from acyclic precursors and a mild, halogenation-initiated method for their aromatization under focused microwave irradiation

  2013cites this paper
• Structure-based design and synthesis of novel pseudosaccharine derivatives as antiproliferative agents and kinase inhibitors.

  2013cites this paper
• Development of New Breast Cancer Resistance Protein Inhibitors

  2013cites this paper
• Microwave-accelerated Dimroth rearrangement for the synthesis of 4-anilino-6-nitroquinazolines. Application to an efficient synthesis of a microtubule destabilizing agent

  2010cites this paper
• Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4(3)H-ones

  2010cites this paper
• Toward the Comprehensive Systematic Enumeration and Synthesis of Novel Kinase Inhibitors Based on a 4-Anilinoquinazoline Binding Mode

  2010cites this paper
• Heteroannulated Quinazoline and Quinazolinone Derivatives from (Z)-2-[1-Benzamido-2-(3,4,5-trimethoxyphenyl)]vinyl-3,1-benzoxazin-4(3H)-one

  2010cites this paper
• Synthesis of Quinazolines as Tyrosine Kinase Inhibitors

  2009cites this paper
• Inhibition of vascular endothelial growth factor receptor signaling in angiogenic tumor vasculature.

  2009cites this paper